Contrasting Stevanato Group (NYSE:STVN) and Perspective Therapeutics (NYSE:CATX)

Stevanato Group (NYSE:STVN) and Perspective Therapeutics (NYSE:CATX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Volatility and Risk

Stevanato Group has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Earnings and Valuation

This table compares Stevanato Group and Perspective Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	$1.09 billion	4.92	$157.62 million	€0.55 ($0.60)	32.93
Perspective Therapeutics	$1.43 million	508.99	-$46.51 million	N/A	N/A

Stevanato Group has higher revenue and earnings than Perspective Therapeutics.

Profitability

This table compares Stevanato Group and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.27%	10.89%	6.33%
Perspective Therapeutics	N/A	-32.87%	-28.06%

Analyst Recommendations

This is a summary of current recommendations for Stevanato Group and Perspective Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0	2	3	0	2.60
Perspective Therapeutics	0	0	8	1	3.11

Perspective Therapeutics has a consensus price target of $21.43, suggesting a potential upside of 83.31%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Perspective Therapeutics is more favorable than Stevanato Group.

Insider & Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 3.5% of Perspective Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Perspective Therapeutics beats Stevanato Group on 8 of the 13 factors compared between the two stocks.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.